Alcobra Hopes To Continue Development In Fragile X On Quality Of Life Findings
This article was originally published in The Pink Sheet Daily
Executive Summary
Israeli firm contends that secondary endpoints address factors that matter most to patients, clinicians and caregivers, even though its metadoxine failed on the primary efficacy measure.